Chemotherapy for sensitive recurrent ovarian cancer generally still advocates platinum-containing combination chemotherapy regimens, such as TC, carboplatin + liposomal adriamycin, cisplatin + topotecan, etc. For drug-resistant recurrent ovarian cancer, non-platinum single-agent chemotherapy is mostly used, such as topotecan weekly therapy and gemcitabine weekly therapy, etc. The common advantage of these two drugs is that they have no accumulation toxicity. If these patients can get some control of their tumors and maintain platinum-free treatment interval >1 year, it is possible to reverse platinum resistance. Usually, the longer the platinum-free interval, the higher the proportion of platinum re-sensitization, and at this time, it is still possible to obtain good efficacy by using platinum-based combination chemotherapy again. Of note is the group of patients with relapses between 6-12 months of complete remission, which was classified as partially sensitive relapses in the 2009 and 2010 editions of the NCCN guidelines and was eliminated in the 2011 edition, probably because the appropriate management response for this group of patients is not yet known. However, the prognosis of this group of patients is between the sensitive and resistant types, and our own study suggests that it may still be necessary to treat them differently, and that the management strategy should be closer to that of the resistant type. Oral VP16 capsules have a special place in the chemotherapy of recurrent ovarian cancer. Despite its good effect, this drug is generally not used prematurely because of its side effect of inducing leukemia. Studies have concluded that once even early-stage ovarian cancer recurs, the prognosis is as poor as that of late-stage ovarian cancer; and most recurrent ovarian cancers have no chance of cure. Therefore, it is most important to maintain a good quality of life for patients to the maximum extent possible in the treatment of recurrent ovarian cancer. Palliative care occupies an important position.